Journal Article

DKFZ-2022-00119

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer.

Mukama, T. (First author)DKFZ* ; Fortner, R. T.DKFZ* ; Katzke, V.DKFZ* ; Hynes, L. C.DKFZ* ; Petrera, A. ; Hauck, S. M. ; Johnson, T. S.DKFZ* ; Schulze, M. ; Schiborn, C. ; Rostgaard-Hansen, A. L. ; Tjønneland, A. ; Overvad, K. ; Pérez, M. J. S. ; Crous-Bou, M. ; Chirlaque, M.-D. ; Amiano, P. ; Ardanaz, E. ; Watts, E. L. ; Travis, R. C. ; Sacerdote, C. ; Grioni, S. ; Masala, G. ; Signoriello, S. ; Tumino, R. ; Gram, I. T. ; Sandanger, T. M. ; Sartor, H. ; Lundin, E. ; Idahl, A. ; Heath, A. K. ; Dossus, L. ; Weiderpass, E. ; Kaaks, R. (Last author)DKFZ*

2022
Nature Publ. Group Edinburgh

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/s41416-021-01697-z

Abstract: CA125 is the best available yet insufficiently sensitive biomarker for early detection of ovarian cancer. There is a need to identify novel biomarkers, which individually or in combination with CA125 can achieve adequate sensitivity and specificity for the detection of earlier-stage ovarian cancer.In the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we measured serum levels of 92 preselected proteins for 91 women who had blood sampled ≤18 months prior to ovarian cancer diagnosis, and 182 matched controls. We evaluated the discriminatory performance of the proteins as potential early diagnostic biomarkers of ovarian cancer.Nine of the 92 markers; CA125, HE4, FOLR1, KLK11, WISP1, MDK, CXCL13, MSLN and ADAM8 showed an area under the ROC curve (AUC) of ≥0.70 for discriminating between women diagnosed with ovarian cancer and women who remained cancer-free. All, except ADAM8, had shown at least equal discrimination in previous case-control comparisons. The discrimination of the biomarkers, however, was low for the lag-time of >9-18 months and paired combinations of CA125 with any of the 8 markers did not improve discrimination compared to CA125 alone.Using pre-diagnostic serum samples, this study identified markers with good discrimination for the lag-time of 0-9 months. However, the discrimination was low in blood samples collected more than 9 months prior to diagnosis, and none of the markers showed major improvement in discrimination when added to CA125.

Note: #EA:C020#LA:C020# /2022 May;126(9):1301-1309

---

Contributing Institute(s):

1. C020 Epidemiologie von Krebs (C020)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2022

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---